We asked a similar question about the HIV patients that were getting Leronlimab weekly when covid was just starting. Did any of these patient come down with Covid and never received an answer to that question.

You would think you could pole with questions your own patients in your own HIV trial about… “if” they caught Covid while taking Leronlimab weekly and we would know easily the value of seeking Covid indications. Then add it to a trial somewhere as maybe a prep drug… not as if there was a market not being a vaccine and all. But just knowing it worked that way is what we wanted to know to see if even trialing for Covid indications was worth while. The question fell on deaf ears in a conference call. I was a little bummed about that at the time… why not check out that lead and get back to us?